OH-PROAMPAC
1.5.2023 16:18:28 CEST | Business Wire | Press release
ProAmpac, a leader in flexible packaging and material science, will showcase its products at Interpack, a worldwide exhibition for the packaging industry, in Hall 10, Stand D21. The event is scheduled to take place in Dusseldorf, Germany, from 4-10 May.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230501005442/en/
ProActive Recyclable R-2050 is a high-performance mono PE recyclable film that features superior heat resistance, excellent directional tear for easy opening and various barrier properties available to suit even the most sensitive products. (Photo: Business Wire)
"We're thrilled to be back at Interpack this year with sustainable packaging innovation and our expanded capabilities in Europe, Ireland, and the UK. Our recent additions, such as digital printing, spouted and aseptic pouching, and our commitment to ESG goals, enable us to collaborate on the latest innovations in flexible packaging," states Adam Grose, chief commercial officer for ProAmpac.
Sustainable Packaging Innovations
ProAmpac will showcase its sustainable offerings with its ProActive Sustainability® line of packaging. New product innovations on display include:
- ProActive Recyclable R-2050. This high-performance mono PE recyclable film features superior heat resistance, excellent directional tear for easy opening and various barrier properties available to suit even the most sensitive products.
- QUADLFEX Recyclable is a film-based quad packaging solution that is perfect for high-speed filling lines. This packaging can be customized with clear windows and surface finishes and is preapproved for recycling through the in-store drop-off program.
- ProActive Recyclable RP-1000, a recyclable paper-based product that provides barrier protection for dry and non-greasy food products.
- PRO-EVO Recyclable provides excellent grease and edge-wicking resistance without intentionally adding per- and poly-fluoroalkyl substances (PFAS). PRO-EVO Recyclable is also available with a high moisture barrier to maintain the freshness of pet foods.
- RAP Packaging Products keeps food to-go fresh and offers an elevated appearance in either a hot cabinet or a chiller. Also, by weight, the largest packaging component is paperboard and paper sourced from well-managed forests, which is widely recyclable in fibre streams. ProAmpac’s food to-go packaging solutions are 2023 OPRL 90/10 compliant.
- ProActive PIR film contains 30% polyethylene-based postindustrial recycled content, meets UK Plastic Packaging Tax guidelines for tax exemption and is OPRL compliant for front-of-store drop-off. All virgin material and film used to produce ProActive PIR film are EU food contact grade materials, which comply with Regulation (EU) No 10/2011 and have also undergone additional NIAS testing.
Thought Leadership
On Monday, 8 May, at 11:00 am, Sal Pellingra, the vice president of global package design, applications, and business development at ProAmpac, will be presenting ProAmpac's Approach to Sustainability at the Interpack TV Stage, situated between Halls 7 and 9 at the North Entrance. During the presentation, Sal will highlight sustainable market trends and ProAmpac’s collaborative approach to commercialization of new ProActive Sustainability® technologies toward a more circular economy.
To set up a meeting during the show or learn how ProAmpac’s team can help you, please contact Events@ProAmpac.com or visit ProAmpac.com.
About ProAmpac
ProAmpac is a leading global flexible packaging company with a comprehensive product offering, providing creative packaging solutions, industry-leading customer service and award-winning innovation to a diverse global marketplace. ProAmpac’s approach to sustainability – ProActive Sustainability® – provides innovative sustainable flexible packaging products to help our customers achieve their sustainability goals. We are guided in our work by five core values that are the basis for our success: Integrity, Intensity, Innovation, Involvement and Impact. Cincinnati-based ProAmpac is owned by Pritzker Private Capital along with management and co-investors. For more information, visit ProAmpac.com or contact Media@ProAmpac.com.
About Pritzker Private Capital
Pritzker Private Capital partners with middle-market companies based in North America with leading positions in the manufactured products and services sectors. The firm's differentiated, long duration capital base allows for efficient decision-making, broad flexibility with transaction structure and investment horizon, and alignment with all stakeholders. Pritzker Private Capital builds businesses for the long term and is an ideal partner for entrepreneur- and family-owned companies. Pritzker Private Capital is a signatory to the United Nations Principles for Responsible Investment (PRI). For more information, visit PPCPartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230501005442/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
